Navigation Links
Current Flu Season Worst in 4 Years
Date:4/17/2008

Vaccine wasn't a good match for circulating viruses, CDC says

THURSDAY, April 17 (HealthDay News) -- The current U.S. flu season has been the worst in four years, due, in part, to a vaccine that was not a good match for certain circulating strains of flu virus, U.S. health officials said Thursday.

For strains of influenza A (H3N2) -- the most prevalent virus during the 2007-08 season, the vaccine was 58 percent effective. But it was 100 percent ineffective against influenza B infections, leaving an overall vaccine success rate of about 44 percent, according to the U.S. Centers for Disease Control and Prevention.

"Most of the circulating influenza viruses this season have been less than optimally matched to the viruses in the vaccine," Dr. Dan Jernigan, deputy director of CDC's Influenza Division, said during a teleconference. "However, the vaccine did provide substantial protection against the predominant influenza virus circulating this season -- the H3N2 influenza A virus. Those people vaccinated were 58 percent less likely to have H3N2 infection than those not vaccinated."

The CDC researchers realized that two of the three circulating strains of flu this season did not match the strains contained in the vaccine, based on results of a study done in Marshfield, Wisc.

The CDC began working with the Marshfield Clinic in central Wisconsin to gauge the effectiveness of influenza vaccines during the flu season. Almost all people in Marshfield receive their health care from the clinic, according to a report in the April 18 issue of the CDC's Morbidity and Mortality Weekly Report.

This flu season, Type A H3N2 Brisbane strain has caused most of the illnesses but was not in the vaccine. The influenza A Florida strain, also not in the vaccine, has also caused sickness.

Jernigan noted that while this season's flu vaccine wasn't perfect, this year's results support getting vaccinated, even in years when the vaccine match is less than optimal.

"Although influenza A viruses have predominated this season, the most recently isolated viruses are influenza B viruses," Jernigan said. This year's vaccine is ineffective against influenza B viruses, he said.

Although the overall effectiveness of this year's vaccine was 44 percent, it has been higher in some years and lower in others, Jernigan said. "In the last 20 seasons, 16 have had good matches, and there have been four that were less than optimal matches," he said.

During the 1997-98 flu season, the vaccine's effectiveness was essentially zero, Jernigan said, adding that was the first year the Type A H3N2 influenza virus appeared.

In some years, the flu vaccine has had an effectiveness level of 70 percent, Jernigan said.

During the current flu season, the number of deaths peaked at 9.1 percent of all reported deaths, Jernigan said. "The number of deaths exceeded the epidemic threshold for 13 consecutive weeks," he said.

There were 66 flu-related deaths of children, 56 of whom weren't vaccinated, were improperly vaccinated or were too young to be vaccinated, Jernigan said.

During the 2003-04 season, deaths peaked at more than 10 percent and remained above the epidemic threshold for nine weeks, Jernigan said.

Each flu season, there are three different strains of influenza virus circulating. Different strains appear at different times, and different strains predominate, Jernigan explained. In addition, each of the three strains can respond differently to the flu vaccine.

It is this fluid flu picture that necessitates changing the vaccine from year to year, Jernigan said.

Since it requires almost a year to prepare the vaccine, decisions about the strains to include in the vaccine are often an educated guess.

But a study published in the April 17 issue of the journal Science could eliminate much of that guess work. Researchers reported that flu viruses originate in East Asia and Southeast Asia, and it takes about eight to nine months before these new viruses reach western Europe and North America.

Jernigan said the CDC is currently involved in promoting better surveillance of emerging flu viruses in East Asia and Southeast Asia. The hope is that these surveillance efforts will lead to more effective and better-matched vaccines.

According to the CDC, each year from 5 percent to 20 percent of the U.S. population gets the flu. More than 200,000 people are hospitalized from flu complications, and about 36,000 people die from the disease. Some people, such as older people, young children, and people with certain health conditions, are at high risk for serious flu complications.

More information

To learn more about the flu, visit the U.S. Centers for Disease Control and Prevention.



SOURCES: April 17, 2008, teleconference with Dan Jernigan, M.D., deputy director, Influenza Division, U.S. Centers for Disease Control and Prevention, Atlanta; April 18, 2008, CDC's Morbidity and Mortality Weekly Report


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
2. Keith Denner Extends Current Technologys Chairman and CEO Options
3. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Merck & Co., Inc. Who Invested in the Merck & Co., Inc. Employee Savings and Security Plan
4. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of WellPoint, Inc. Who Invested in the WellPoint Retirement Savings Plan
5. China Bionanometer Industries (CBIU) Describes their Current Production Capacity and Product Lines
6. One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
7. Current and Emerging Therapies Have No Advantage Over Pfizers Lyrica in Their Effect on Patients Quality of Life in the Treatment of Diabetic Neuropathy
8. Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers
9. U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer
10. Current Blood Sugar Control Test Results Inaccurate
11. Wild Childs Quit Nits Offers a Safe, Natural Alternative to Current Toxic Head Lice Products
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Current Flu Season Worst in 4 Years
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first name ... the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to products ... as ANSI, ISO and proven test methods used in the field of Vision ...
(Date:3/27/2017)... ... March 27, 2017 , ... Metabolism and ... at Women’s Excellence will help patients lose weight and keep it off. , ... specialists at Women's Excellence will measure BMI, body fat composition, and Calcium and ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association ... chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. ... “Increasingly, supply chain and value analysis professionals have a ‘seat at the table’ ...
(Date:3/27/2017)... ... 27, 2017 , ... Sodium determination is consistently becoming more ... expert user knowledge. In a live webinar on April 11th and October 3rd, ... accurate, determination of sodium. , It has long been known that too much ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths ... Assembly Bill (AB) 1512, which proposes a tax on prescription opioids to fund ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... VANCOUVER, British Columbia, March 27, 2017  Sophiris ... "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ... with urological diseases, today reported fourth quarter and ... highlights. Key Corporate Highlights: ... for Localized Prostate Cancer. During 2016, the Company ...
(Date:3/27/2017)... VANCOUVER , March 27, 2017 /PRNewswire/ - INVICTUS ... OTC: IVITF; FRA: 8IS) Invictus MD is pleased to ... common shares for trading on the TSX Venture Exchange.  ... the TSXV follows a year of significant achievements for ... The successful test crops at AB Laboratories Inc. ("AB ...
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
Breaking Medicine Technology: